Probability of Prostate Cancer with PI-RADS 3 Lesions

Understanding PI-RADS 3 Lesions

PI-RADS 3 lesions are considered "equivocal" for the presence of clinically significant prostate cancer, creating uncertainty in clinical decision-making, according to the European Urology guidelines 1
The overall probability of clinically significant prostate cancer in PI-RADS 3 lesions ranges from approximately 17-31% according to large validation studies 2, 3
PI-RADS v2 assessment categories are based on combinations of predefined mpMRI features, weighted for likelihood of malignancy, but do not incorporate clinical factors such as PSA density, as stated in the European Urology guidelines 4, 5

PSA density is one of the strongest predictors for the presence of clinically significant prostate cancer, as reported by the European Urology guidelines 6
The European Association of Urology guidelines suggest considering biopsy for PI-RADS 3 lesions based on additional risk factors, with PSA density being a key consideration 6, 7

The quality of mpMRI and radiologist expertise significantly impacts the accuracy of PI-RADS scoring and subsequent risk assessment, according to the European Association of Urology guidelines 7
Neither PI-RADS nor PSA density is perfect - some clinically significant cancers may be missed even with careful risk stratification, as noted in the European Urology guidelines 7